Ongoing data from the phase 3 RESPONSE trial of ruxolitinib for polycythemia vera

At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St Thomas’ NHS Foundation Trust, London, UK, provides an update on the phase 3 RESPONSE trial, which compared the JAK1/2 inhibitor, ruxolitinib, versus best available therapy in patients with polycythemia vera who were intolerant of or resistant to first-line therapy with hydroxyurea.

Share this video  
Similar topics